U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C28H30N6OS
Molecular Weight 498.642
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MASITINIB

SMILES

CN1CCN(CC2=CC=C(C=C2)C(=O)NC3=CC=C(C)C(NC4=NC(=CS4)C5=CN=CC=C5)=C3)CC1

InChI

InChIKey=WJEOLQLKVOPQFV-UHFFFAOYSA-N
InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)

HIDE SMILES / InChI

Molecular Formula C28H30N6OS
Molecular Weight 498.642
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases. AB Science is developing masitinib in multiple sclerosis and alzheimer's disease. Masitinib targets kinases, including c-Kit, PDGFR, and Lyn. It is used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Masivet

Approved Use

Treatment of non-resectable dog mast cell tumours (Grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor.

Launch Date

2008
PubMed

PubMed

TitleDatePubMed
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
2008 Jan
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
2009
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
2009 Sep 30
[New drugs for small animals in 2009].
2010
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
2010 Dec
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.
2010 Feb 4
Drug-induced minimal change nephropathy in a dog.
2010 Mar-Apr
The complexity of the complicity of mast cells in cancer.
2010 May
Clinical trial on the efficacy of masitinib in canine IBD.
2010 Nov 6
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
2011 Oct 30
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
2013 Apr 15
Patents

Sample Use Guides

6 mg/kg/day
Route of Administration: Oral
In Ba/F3 cells expressing human wild-type Kit, Masitinib inhibits SCF (stem cell factor)-induced cell proliferation with an IC50 of 150 nM, while the IC50 for inhibition of IL-3-stimulated proliferation is at approximately >10 µM. In Ba/F3 cells expressing PDGFRα, Masitinib inhibits PDGF-BB-stimulated proliferation and PDGFRα tyrosine phosphorylation with IC50 of 300 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:06:17 GMT 2023
Edited
by admin
on Fri Dec 15 16:06:17 GMT 2023
Record UNII
M59NC4E26P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MASITINIB
DASH   INN   MART.   MI   WHO-DD  
INN  
Official Name English
4-((4-METHYLPIPERAZIN-1-YL)METHYL)-N-(4-METHYL-3-((4-PYRIDIN-3-YL-1,3-THIAZOL-2-YL)AMINO)PHENYL)BENZAMIDE
Systematic Name English
MASITINIB [MI]
Common Name English
masitinib [INN]
Common Name English
MASITINIB [MART.]
Common Name English
Masitinib [WHO-DD]
Common Name English
KINAVET
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C1967
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
EU-Orphan Drug EU/3/04/251
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
WHO-VATC QL01XE22
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
FDA ORPHAN DRUG 285309
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
FDA ORPHAN DRUG 210505
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
EMA ASSESSMENT REPORTS MASIVIERA (REFUSED: PANCREATIC NEOPLASMS)
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
EU-Orphan Drug EU/3/05/286
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
FDA ORPHAN DRUG 201005
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
EMA ASSESSMENT REPORTS MASICAN (REFUSED: GASTROINTESTINAL STROMAL TUMORS)
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
FDA ORPHAN DRUG 201505
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
EU-Orphan Drug EU/3/04/251
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
EU-Orphan Drug EU/3/04/242
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
Code System Code Type Description
EU-Orphan Drug
EU/3/04/251(POSITIVE)
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY TREATMENT OF MALIGNANT GASTROINTESTINAL STROMAL TUMOURS 20/12/2004 POSITIVE
CHEBI
63450
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
EPA CompTox
DTXSID001000207
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
SMS_ID
100000124415
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
CAS
790299-79-5
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
NCI_THESAURUS
C79910
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
WIKIPEDIA
Masitinib
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
ChEMBL
CHEMBL1908391
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
PUBCHEM
10074640
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
DRUG BANK
DB11526
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
MESH
C526575
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
FDA UNII
M59NC4E26P
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
INN
8779
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
MERCK INDEX
m7092
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY Merck Index
EVMPD
SUB32266
Created by admin on Fri Dec 15 16:06:17 GMT 2023 , Edited by admin on Fri Dec 15 16:06:17 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY